Table 3.
Baseline characteristics of enrolled participants for each trial included in meta-analysis: II
| Author (year) | Age (yrs) (mean or median) (I/C) | Sex ratio Male/Female | Participants randomised/includedd, Treatment administeredc | Proportion HIV infected at baselinea | Proportion with MDR-TBa |
|---|---|---|---|---|---|
| Martineau 2011 [21] | 30.7 (24.5–41.5) /30.5 (24.8–38.4)b | 98/28 | 146/126, at 0, 2, 4 & 6 weeks | 5/93 (5.4) | 1/135 (0.7) |
| Daley 2015 [16] | 41·6 ± 15·1/ 43·7 ± 14·3″ | 189/58 | 247/211, at 0, 2, 4, & 6 weeks | 0/209 (0) | 1/209 (0.5) |
| Farazi 2017 [36] | 52.4 ± 17.6/ 51.8 ± 18.2″ | 31/29 | 68/60 at week 0 only | 0/60 (0) | ND |
| Mily 2015 [18] | 27.2 ± 8.0 / 26.7 ± 8.1″ | 177/111 | 288/260 daily for 8 weeks | ND | 7/260 (2.7) |
| Nursyam 2006 [37] | 29.85 ± 11.08 / 32.55 ± 11.6″ | 39/28 | 67/67 daily for 6 weeks | 0/67 (0) | ND |
| Ralph 2013 [20] | 29 (15–65)/ 26 (15–73) b | 131/69 | 200/164 at 0 & 4 weeks | 19/123 (15.4) | 2/164 (1.2) |
| Salahuddin 2013 [14] | 27.8 ± 13.2 / 28.3 ± 14.1″ | 141/118 | 259/259 at 0 & 4 weeks | ND | ND |
| Tukvadze 2015 [39] | 32.4 6 ± 10.6 / 34.1 6 ± 12.4″ | 127/72 | 199/192 weekly for 8 weeks,then fortnightly for 8 weeks | 3/184 (1.6) | 23/192 (12.0) |
| Wejse 2009 [38] | 37 ± 13/ 38 ± 14” | 222/145 | 367/241 at 0,20 & 32 weeks | 82/240 (34.2) | ND |
| Johnson 2003 [40] | 26.7 ± 7 / 27.4 ± 7″ | 75/35 | 110/110 daily for 4 1/2 weeks | 0/110 (0) | 2/110 (1.8) |
| Mayanja-Kizza 2005 [41] | 31.0 ± 7.1/ 31 ± 7.2″ | 113/74 | 187/187 daily for 8 weeks | 187/187 (100) | ND |
| Pedral-Sampaio 2003 [44] | 31.6 ± 10.9/ 28.0 ± 6.2″ | 16/15 | 31/31twice weekly for 4 weeks | 0/31 (0) | ND |
| Willis 1996 [42] | 28.1 ± 0.7 / 29.9 ± 1.0″ | NM | 107/107 daily for 16 weeks | 107/107 (100) | ND |
| Mahakalkar 2017 [43] | 31.96 ± 13.14 / 29.79 ± 11.12″ | 27/21 | 62/48 daily for 8 week | ND | NM |
| Ganmaa 2017 [15] | 31 (23–44) / 35 (25–47) b | 256/134 | 390/390 at 0, 2, 4 & 6 weeks | ND | 21/390 (5.4) |
I/C Intervention & control groups, Anti-TB Anti-tuberculosis, ND not determined, NM not mentioned, MDR-TB multi-drug resistance tuberculosis, yrs. years, HIV human immuno deficiency virus
a: where denominators are less than total number of included participants, data are missing; “:mean age; b:median age; c: frequency at which adjunct treatment was administered; d:number of participants included in the final analysis